RARB and neoplasm: To explore additional mechanisms of tumor regression caused by EAD, and to identify drug targets other than RAR-β, we performed high-throughput gene expression profiling analysis of MDA-MB-231 cells treated with entinostat, ATRA, and doxorubicin as single, double, and triple combinations.